Compare · MDXG vs SNOA
MDXG vs SNOA
Side-by-side comparison of MiMedx Group Inc (MDXG) and Sonoma Pharmaceuticals Inc. (SNOA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDXG and SNOA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDXG is the larger of the two at $468.4M, about 84.9x SNOA ($5.5M).
- MDXG has been more active in the news (7 items in the past 4 weeks vs 3 for SNOA).
- MDXG has more recent analyst coverage (7 ratings vs 0 for SNOA).
- Company
- MiMedx Group Inc
- Sonoma Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $468.4M
- $5.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 7
- 3
- Recent ratings
- 7
- 0
MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Latest MDXG
- SEC Form SCHEDULE 13G filed by MiMedx Group Inc
- MIMEDX to Participate in Upcoming Investor Conferences
- SEC Form 425 filed by MiMedx Group Inc
- SEC Form 8-K filed by MiMedx Group Inc
- SEC Form 10-Q filed by MiMedx Group Inc
- MIMEDX Announces Third Quarter 2026 Operating & Financial Results
- MIMEDX Announces $25 Million Patent License Agreement
- SEC Form 425 filed by MiMedx Group Inc
- SEC Form 8-K filed by MiMedx Group Inc
- MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
Latest SNOA
- SEC Form S-3 filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- Amendment: SEC Form 8-A12B/A filed by Sonoma Pharmaceuticals Inc.
- SEC Form 8-K filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.